08:49 AM EDT, 09/10/2024 (MT Newswires) -- Health care stocks were steady premarket Tuesday with the iShares Biotechnology ETF (IBB) unchanged and the Health Care Select Sector SPDR Fund (XLV) marginally lower recently.

Viridian Therapeutics ( VRDN ) shares were up over 17% after the company said a phase 3 clinical trial of VRDN-001 or veligrotug, a potential treatment of active thyroid eye disease, met all primary and secondary endpoints at 15 weeks after five infusions.